Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1998-11-10
2000-08-29
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
A61K 3127, A61K 31275
Patent
active
061109681
ABSTRACT:
Methods are provided for measuring the accumulation of advanced glycosylation endproducts (AGEs), and for lowering the accumulation of advanced glycosylation endproducts, which are predicated on the discovery that such AGEs and their precedent glycotoxins are present in tobacco and its byproducts. More particularly, the methods focus on the observation that individuals who smoke or otherwise use tobacco have increased levels of AGEs relative to non-smoking individuals. The present methods relate to the measurement of AGE levels in both individuals and in tobacco and its byproduct, smoke, and to the treatment of such individuals with agents capable of reacting with glycosylation products to either avert or diminish the accretion of AGEs in the body. Methods are also provided for the evaluation of the tobacco products to determine their storage status and organoleptic capacity and potential, for the treatment of the ambient atmosphere to lower AGE levels, and for the treatment of the tobacco products and combustion byproducts to lower AGE levels therein. For example, air or other samples may be taken and evaluated by a dosimeter or like device, to determine whether AGE levels exceed normal, after which measures could be implemented to remediate the ambient condition. Likewise, filters and similar devices for removing AGEs from tobacco smoke are provided. All such methods and corresponding materials are contemplated and included.
REFERENCES:
patent: 2258321 (1941-10-01), Ericks
patent: 2289541 (1942-07-01), Bricks et al.
patent: 2300570 (1942-11-01), Heuser et al.
patent: 2375659 (1945-05-01), Jones et al.
patent: 2721217 (1955-10-01), Peters et al.
patent: 2928829 (1960-03-01), Mull
patent: 2951843 (1960-09-01), Haack et al.
patent: 3006913 (1961-10-01), Mull
patent: 3053732 (1962-09-01), Greenhalgh
patent: 3055882 (1962-09-01), Mull
patent: 3055883 (1962-09-01), Mull
patent: 3081222 (1963-03-01), Hagemann et al.
patent: 3098066 (1963-07-01), Mull
patent: 3101336 (1963-08-01), James et al.
patent: 3178433 (1965-04-01), Mull
patent: 3183241 (1965-05-01), Oja
patent: 3200111 (1965-08-01), Paquette
patent: 3201459 (1965-08-01), Coda et al.
patent: 3202710 (1965-08-01), Bolger
patent: 3283003 (1966-11-01), Jack et al.
patent: 3291829 (1966-12-01), Mull
patent: 3317545 (1967-05-01), Albrecht et al.
patent: 3320195 (1967-05-01), Braun
patent: 3364220 (1968-01-01), Biel et al.
patent: 3506680 (1970-04-01), Berger et al.
patent: 3637850 (1972-01-01), Houlihau et al.
patent: 3681504 (1972-08-01), Johnston et al.
patent: 3746764 (1973-07-01), Nordmann et al.
patent: 3803324 (1974-04-01), Winter et al.
patent: 3978060 (1976-08-01), Forsythe et al.
patent: 3980774 (1976-09-01), Hegarty et al.
patent: 3991209 (1976-11-01), Forsythe et al.
patent: 4161541 (1979-07-01), Rasmussen
patent: 4271190 (1981-06-01), Bertelmann et al.
patent: 4471137 (1984-09-01), Barton et al.
patent: 4544759 (1985-10-01), Hlavaka et al.
patent: 4665192 (1987-05-01), Cerami et al.
patent: 4680300 (1987-07-01), Nelson et al.
patent: 4731383 (1988-03-01), Erczi et al.
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4908446 (1990-03-01), Ulrich et al.
patent: 4978684 (1990-12-01), Cerami et al.
patent: 4983604 (1991-01-01), Ulrich et al.
patent: 5006523 (1991-04-01), Atwal
patent: 5017696 (1991-05-01), Farmar et al.
patent: 5140048 (1992-08-01), Ulrich et al.
patent: 5189046 (1993-02-01), Burch et al.
patent: 5196450 (1993-03-01), Sjoerdsma et al.
patent: 5296498 (1994-03-01), Malen et al.
patent: 5336689 (1994-08-01), Weber et al.
Acharya et al. 1988. Biochemistry27(12): 4522-9.
Baylin et al. (1975) Experimentia 31:562-64.
Beaven et al. (1969) J. Pharm. Exp. Ther. 165:14-22.
Brown et al. Abst., Assoc. for Minority Phys., Oct. 27, 1989, Washington DC.
Brown et al. (1990) J. Am. Soc. Nephrology, vol. I, No. 4, p. 329.
Brownlee CA 111:70141f.
Brownlee et al. CA 105:72441d.
Brownlee et al. (1985) Diabetes 34:938-40.
Brownlee et al. (1986) Diabetes 35 (Suppl. 1):42A.
Brownlee et al. 1986. Science 232: 1629-32.
Brownlee et al. 1984. Ann. Int. Med. 101: 527-37.
Brownlee et al. 1983. J. Exp. Med. 158: 1739-44.
Bucala et al. 1984, PNAS 1984, 81:105-109.
Bucala 1985, PNAS 82:8439-8442.
Bunn et al. 1975. Biochem. Biophys. Res. Comm. 67: 103-9.
Cameron et al. (1992) Diatetologia 35:946-50.
Carroll et al. (1984) Fed. Proc. 43:Abst.2514.
Dabrowski et al. (1983) Acta. Physiol. Pol. 34:91-7.
Dabrowski et al. (1984) Agents and Actions 14:458-60.
Ebetino et al. 1962. J. Org. Chem. 27: 188-91.
Ebetino et al. 1964. J. Org. Chem. 29: 2582-5.
Eble et al. (1983) J. Biol. Chem. 258:9406-12; CA 99:219(84008p).
Finot. 1982. in Food and Nutritional Aspects. Feeney and Whitaker, eds. American Chemical Society 198: 91-124.
Flier et al. (1988) New Eng. J. Med. 318:1315-21.
Fong et al. (1989) diabetes 38:84A.
Geisen, K. (1987) Abst., 22nd Annual Meeting of the German Diabetes Association (translated by P. Ulrich).
Giambrone et al. (1989) Diabetes 38, Suppl.2:83A.
Godfrey. 1962. Doctoral Dissertation. U. of London.
Harding, J.J. (1985) Adv. Prot. Chem. 37:247-66.
Hayase et al., J. Biol. Chem., 263:3758-3764 (1989).
Hollis et al. (1984) Exp. Mol. Path. 41:207-17.
Hollis et al. (1985) Diabetologia 28:282-5.
Hollis et al. (1984) Fed. Proc. 43:Abst.2513.
Hollis et al. (1985) Exp. Mol. Path. 43:90-6.
Kihara et al. (1991) Proc. Natl. Acad. Sci. USA 88:6107-11.
Kohn et al. 1984. Diabetes 33(1): 57-9.
Koenig et al. 1977. J. Biol. Chem. 252:2992-7.
Kumari et al. (1991) Diabetes 40:107985.
Lee AT and Cerami, A. 1987, PNAS 84:8311-8314.
Lee et al. (1994) FASEB Journal 8:545-550.
Levine et al. (1969) Ann. New York Acad. Sci., pp. 246-256.
Levine et al. (1966) Biochem. Pharmacol. 15:841-9.
Lewis et al. (1990) Exp. Eye Res. 50:463-7.
Lewis et al. CA 113:34670k.
Lindberg et al. (1966) Acta. Obst. Gyn. (Scandianav) 45:131-9.
Maillard. C.R. Acad. Sci. 154: 66-8.
Merk Index (1983) 10th ed., P.66: #444.
Merk Index (1989) 11th ed., #453: Aminoguanidine.
Merk Index (1976) 9th ed., p. 60: #447.
Monnier et al. 1984. Proc. Natl. Acad. Sci. 81: 583-7.
Monnier and Cerami. 1983. in Maillard Reaction in Food and Nutrition. Waller, ed. American Chemical Society 215: 431-49.
Monnier and Cerami. 1983. Biochem. Biophys. Acta. 760: 97-103.
Monnier and Cerami. 1982. Clin. Endocrinol. Metab. 11: 431-52.
Monnier and Cerami. 1981. Science 211: 491-3.
Murdock et al. 1982. J. Med. Chem. 25: 505-18.
Nicholls et al. (1989) Lab. Invest. 60:486-91.
Odetti et al. (1990) Diabetes 39:796-801.
Oimomi et al. (1989) Agric. Biol. Chem. 53:1727-8.
Orlidge et al. (1982) Arteriosclerosis 2:142-50.
Owens et al. (19821) Arteriosclerosis 1:265-72.
Oxlund et al., Abst., Prog. for the Symp. Glycated Prot. in Diabetes Mellitus, Adelaide, South Australia, 11/16-8/88.
Oxlund et al. (1992) Diabetologia 35:19-25.
Ponger et al. 1984. Proc. Natl. Acad. Sci. USA 81: 2684-8.
Potekhin et al. 1973. Zhurnal Organicheskoi Khimii 9:1180-6.
Sell, D. and Monnier V., J. Biol. Chem., 264:21597-21602 (1989).
Soulis et al. Abst., NIH Conf. Maillard Reaction in Aging, Diabetes, Nutrition, Bethesda, Maryland, 9/22-3/88.
Soulis et al., Abst., Prog. for the Symp. Glycated Prot. in Diabetes Mellitus, Adelaide, South Australia, 11/16-8/88.
Soulis-Liparot et al. (1991) Diabetes 40:1328-34.
Stoner et al. 1985. Agents and Actions 17: 5-9.
Sundberg et al. 1990. J. Med. Chem. 33: 298-307.
Tai et al. 1984. J. Med. Chem. 27: 236-8.
Vlassara et al. (1992) Proc. Natl. Acad. Sci. USA 89:12043-7.
Yamashita et al. (1989) Diabetes 38:25A.
Bucala Richard J.
Cerami Anthony
Cerami Carla J.
Founds Henry W.
Vlassara Helen
Cintins Marianne M.
Kim Vickie
The Picower Institute for Medical Research
LandOfFree
Methods for treatment predicated on the presence of advanced gly does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment predicated on the presence of advanced gly, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment predicated on the presence of advanced gly will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1250465